Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction
Bosch, Lena; Lam, Carolyn S.P.; Gong, Lingli; Chan, Siew Pang; Sim, David; Yeo, Daniel; Jaufeerally, Fazlur; Leong, Kui Toh Gerard; Ong, Hean Yee; Ng, Tze Pin; Richards, Arthur Mark; Arslan, Fatih; Ling, Lieng H.
(2017) European Journal of Heart Failure, volume 19, issue 12, pp. 1664 - 1671
(Article)
Abstract
Background: Right ventricular (RV) dysfunction is recognized as a major prognostic factor in left-sided heart failure (HF). However, the relative contribution of RV dysfunction in HF with preserved (HFpEF) vs. reduced ejection fraction (HFrEF) is unclear. Methods and results: Right ventricular longitudinal strain (RVLS), tricuspid annular plane systolic excursion (TAPSE)
... read more
and pulmonary artery systolic pressure (PASP) were determined by echocardiography in 657 age- and gender-matched groups of patients with HFpEF [left ventricular ejection fraction (LVEF) ≥50%; n=219] and HFrEF (LVEF <50%; n=219) and in controls without HF (n=219) from an Asian population-based cohort study. Across control to HFpEF and HFrEF groups, RV function deteriorated as measured by RVLS (−26.7 ± 5%, −22.7±6.6% and −18.2 ± 6.7%, respectively) and TAPSE (21.0 ± 3.9, 17.5 ± 5.1 and 14.7 ± 4.7 mm, respectively), whereas PASP increased (26.8 ± 7.1, 34.5 ± 11.9 and 39.3 ± 16.2 mmHg, respectively) (all P<0.001). Controlling for PASP in control, HFpEF and HFrEF subjects, the magnitude of RVLS/PASP (−1.06 ± 0.32, −0.75 ± 0.32 and −0.56 ± 0.36, respectively) and TAPSE/PASP ratios (0.83 ± 0.23, 0.54 ± 0.24 and 0.55 ± 0.29, respectively) similarly decreased across groups. Right ventricular dysfunction (by both TAPSE and RVLS) was independently associated with left ventricular systolic dysfunction and atrial fibrillation, but not with PASP. Among patients with HF, both TAPSE/PASP and RVLS/PASP ratios were related to the composite endpoint of all-cause death and HF hospitalization, even after multivariable adjustment [hazard ratio (HR) 0.33; 95% confidence interval (CI) 0.14–0.74 and HR 3.09; 95% CI 1.52–6.26, respectively], with no difference between HFrEF and HFpEF. Conclusions: Right ventricular dysfunction is present in HFpEF and is even more pronounced in HFrEF for any given degree of pulmonary hypertension. It is independently predicted by left ventricular dysfunction but not by PASP. Right ventricular–arterial coupling is prognostically important in HF regardless of LVEF.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Deformation imaging, Echocardiography, Heart failure, Preserved ejection fraction, Pulmonary hypertension, Right ventricular dysfunction, Cardiology and Cardiovascular Medicine
ISSN: 1388-9842
Publisher: Oxford University Press
Note: Funding Information: This work was supported by a Centre Grant from the National Medical Research Council of Singapore (grant number R-172-003-2190511) and by the Alexandre Suerman MD/PhD programme from the UMC Utrecht. Conflict of interest: C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim and Abbott Diagnostics. A.M.R is supported by a Senior Translational Research Award from the National Medical Research Council of Singapore and is Principal Investigator for the Centre Grant made to the National University Heart Centre, Singapore, which funded this study. He has consulted for, and received research support from, Bayer, Novartis, Merck, Medtronic, Pfizer, Boehringer Ingelheim, Astra Zeneca, Roche Diagnostics, Thermo Fisher, Alere, Critical Diagnostics, and Abbott Diagnostics. All other authors have no conflicts of interest to declare. Funding Information: This work was supported by a Centre Grant from the National Medical Research Council of Singapore (grant number R-172-003-2190511) and by the Alexandre Suerman MD/PhD programme from the UMC Utrecht. Conflict of interest: C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim and Abbott Diagnostics. A.M.R is supported by a Senior Translational Research Award from the National Medical Research Council of Singapore and is Principal Investigator for the Centre Grant made to the National University Heart Centre, Singapore, which funded this study. He has consulted for, and received research support from, Bayer, Novartis, Merck, Medtronic, Pfizer, Boehringer Ingelheim, Astra Zeneca, Roche Diagnostics, Thermo Fisher, Alere, Critical Diagnostics, and Abbott Diagnostics. All other authors have no conflicts of interest to declare. The authors would like to thank the clinicians, clinical research coordinators and sonographers in their institutions who assisted with the conduct of this study. This work was supported by a Centre Grant from the National Medical Research Council of Singapore (grant number R-172-003-2190511) and by the Alexandre Suerman MD/PhD programme from the UMC Utrecht. Conflict of interest: C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim and Abbott Diagnostics. A.M.R is supported by a Senior Translational Research Award from the National Medical Research Council of Singapore and is Principal Investigator for the Centre Grant made to the National University Heart Centre, Singapore, which funded this study. He has consulted for, and received research support from, Bayer, Novartis, Merck, Medtronic, Pfizer, Boehringer Ingelheim, Astra Zeneca, Roche Diagnostics, Thermo Fisher, Alere, Critical Diagnostics, and Abbott Diagnostics. All other authors have no conflicts of interest to declare. Publisher Copyright: © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
(Peer reviewed)